312
Views
8
CrossRef citations to date
0
Altmetric
Pharmacoeconomic Evaluation

Pharmacoeconomics of synthetic therapies for multiple sclerosis

ORCID Icon, , , , &
Pages 1331-1340 | Received 31 Jul 2018, Accepted 03 May 2019, Published online: 15 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now

Articles from other publishers (7)

Steven Simoens. (2022) Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Frontiers in Neurology 13.
Crossref
Simona Toscano, Francesco Patti, Clara Grazia Chisari, Sebastiano Arena, Chiara Finocchiaro, Carmela Elita Schillaci & Mario Zappia. (2022) Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID-19 era. Neurological Sciences 43:4, pages 2253-2261.
Crossref
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Vincenzo Cimino & Giuseppe Milone. (2022) Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. Journal of Clinical Medicine 11:4, pages 942.
Crossref
Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, Simona Toscano, Maria Luca & Francesco Patti. (2021) Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology 269:1, pages 159-183.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 101 234 .
Elizabeth C.S. Swart, Douglas Mager, Natasha Parekh, Rock A. Heyman, Rochelle Henderson, Kiraat Munshi, Gail Bridges & Chester B. Good. (2021) Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy. Multiple Sclerosis and Related Disorders 56, pages 103285.
Crossref
Richard Dodel, Christopher Kruse, Annette Conrads-Frank & Uwe Siebert. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 135 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.